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Background: Current diagnostic modalities are able to accurately detect hemodynamically significant obstructions due to atherosclerosis but are 
unable to detect the underlying inflammatory process that leads to sudden plaque rupture and unexpected cardiac death.
Methods: A simple blood test that accurately measures inflammatory protein markers in serum has been developed. It uses a multiplexed ELISA 
technique to measure 45 biomarkers. Subjects in the study were identified as participants in the Kaiser Permanente Multiphasic Health Checkup. 
Serum from healthy subjects was obtained and frozen between 1985 and 1991. Yearly follow-up hospitalization and mortality records were used to 
select 695 ‘Cases’ from those subjects who had a first acute myocardial infarction (AMI) during the 10 years of follow-up. ‘Controls’ were individually 
matched on age, gender, ethnicity and blood draw date.
Results: Conditional regression modeling was used to identify combinations of biomarkers that were associated with prediction of a future MI. 
Individual biomarkers were tested for their ability to differentiate cases from controls and the Standardized Odds Ratios (SOR) ranged from 1.1 
to 1.8. Multivariate models were then developed based on a) biomarkers treated as continuous variables and b) number of elevated markers as 
the single predictive variable, where the identification of the optimum cutoff for each biomarker was part of the model building process. When 
biomarkers were treated as continuous variables, four markers were found to contribute to the model with individual SOR varying from 1.22 to 1.43. 
When biomarkers were treated as dichotomous variables in the latter model an OR of 11.7 (CI 8.7-15.7) for the group with the highest count of 
elevated markers (count=4) vs. the reference (count=0) was obtained. Both approaches produced models with biomarkers from different pathways 
implicated in cardiovascular disease. The association of the markers remained statistically significant after adjustment for traditional risk factors.
Conclusions: This study demonstrates the feasibility and utility of a multiplexed proteomic based algorithm for the prediction of AMI.
